2月21日《自然医学》披露的特殊病例引发全球关注：一位接受CAR-T治疗的多发性骨髓瘤患者，竟在9个月后遭遇外周T细胞淋巴瘤的突袭。这场抗癌疗法引发的"细胞叛变"，揭开了现代免疫治疗最隐秘的基因暗战。

The FDA accepted odronextamab’s biologics license application resubmission for relapsed/refractory follicular lymphoma after ...

Clinical validation of the Azymetric platform is demonstrated by the accelerated approval of Ziihera® (zanidatamab-hrii), a treatment for advanced HER2-positive biliary tract cancer in adults who have ...

Unlike monoclonal antibodies, bispecific antibodies bind to 2 different antigens simultaneously,[1][1] directing T cells toward cancer cells to exert a cytotoxic killing effect.[1][1] Bispecific ...

At the recent 2025 congress of the European Crohn’s and Colitis Organisation, researchers from Helixon Therapeutics presented the discovery and preclinical characterization of HXN-1002, a bispecific ...

Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why ...

Although immune checkpoint inhibitors have shown noticeable clinical benefits, tumor evasion of single-agent immunotherapy occurs in some patients due to the compensatory role of alternative immune ...

Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well ...

Advisor engaged in evaluating strategic options to maximize shareholder valueCash balance of $76.6 million as of December 31, 2024UTRECHT, The ...

With Lava Therapeutics still smoldering from the decision to dump its lead blood cancer drug, the biotech is now laying off ...

National Biotechnology Conference, gene therapies, bispecific antibodies and other novel modalities—relative newcomers to ...

Summit’s PD-1 bispecific antibody outperformed MSD’s Keytruda in a Phase III trial enrolling patients with lung cancer.